Kingmed Diagnostics(SH:603882) Zheng Quan Zhi Xing·2025-05-30 10:19Core Viewpoint - The company is preparing for its 2024 annual shareholders' meeting, where various proposals will be discussed, including the annual report, auditor reappointment, and compensation plans for management and supervisors. The company has faced significant financial challenges in 2024, with a notable decline in revenue and net profit compared to the previous year [8][24]. Group 1: Meeting Details - The annual shareholders' meeting is scheduled for June 9, 2025, at 14:30, with both on-site and online voting options available for shareholders [1][2]. - The meeting will cover eight proposals, including the annual report and the reappointment of the auditing firm for 2025 [5][6]. Group 2: Financial Performance - In 2024, the company reported a revenue of approximately 7.19 billion yuan, a decrease of 15.81% from 2023 [20]. - The net profit attributable to shareholders was -381.24 million yuan, representing a decline of 159.26% year-on-year [20][24]. - The company’s basic earnings per share for 2024 were -0.82 yuan, down 159.42% from 1.38 yuan in 2023 [20]. Group 3: Operational Strategy - The company aims to enhance operational efficiency by focusing on profit, cash flow, and quality revenue, while also innovating its marketing strategies [13]. - A significant emphasis will be placed on digital transformation and data governance to optimize costs and improve operational efficiency [13][14]. Group 4: Governance and Compliance - The company has established a comprehensive internal control system to ensure effective management and compliance with regulations [18]. - The supervisory board has conducted thorough oversight of the company's financial management and compliance with legal requirements, finding no violations [17][19]. Group 5: Future Outlook - The company plans to reinvest retained earnings into development rather than issuing dividends, reflecting a focus on long-term growth [24][25]. - The board has proposed to continue the engagement with the auditing firm, Lixin, for the 2025 fiscal year, highlighting its established reputation and expertise [27][28].